Predict your next investment

HEALTHCARE | Disease Diagnosis
sema4.com

See what CB Insights has to offer

Founded Year

2017

Stage

Reverse Merger | IPO

Total Raised

$241M

About Sema4

Sema4 is a patient-centered, health intelligence company dedicated to advancing the diagnosis, treatment, and prevention of disease. Sema4 uses advanced network analysis to build better models of human health and deliver personalized insights for patients.

Sema4 Headquarter Location

333 Ludlow Street North Tower, 8th floor

Stamford, Connecticut, 06902,

United States

800-298 6470

Latest Sema4 News

Mount Sinai Health System-backed Sema4 goes public at $3B valuation

Jul 26, 2021

Jul 26, 2021 11:37am Spun out of Mount Sinai in 2017, the Sema4 platform uses machine learning and other artificial intelligence tools to analyze a database of more than 10 million patient genomic profiles and clinical records. (monsitj/GettyImages) Clinical data and genomics company Sema4 debuted on the stock market Friday, raising $500 million to "step on the gas" and accelerate the growth of its healthcare intelligence platform. The Connecticut-based venture of Mount Sinai Health System went public via a SPAC merger at a valuation of around $3 billion. Sema4 announced the planned merger in February after closing a $121 million series C in August 2020. It began trading on the Nasdaq Global Select Market Friday under the ticker symbols “SMFR” and “SMFRW." Spun out of Mount Sinai in 2017, the Sema4 platform uses machine learning and other artificial intelligence tools to analyze a database of more than 10 million patient genomic profiles and clinical records, with the goal of improving physicians’ ability to diagnose, manage and ultimately prevent disease. The company has entered into various partnerships with health systems to build genomics programs, including Evanston and AdventHealth. Sema4 ’s healthcare intelligence platform aims at building models capable of predicting the courses of conditions and individual outcomes. The company intends to use the influx of capital – approximately $500 million in cash proceeds – to support its organic operating needs and capitalize on inorganic opportunities to accelerate growth through the acquisition of complementary businesses. The company also plans to use the funds to increase uptake of Sema4’s health platforms in healthcare systems and investments in integration. “With the capital raised from this successful transaction, we are well-positioned to help further close the gap between the practice of medicine and the availability of more clinically actionable guidance in order to improve the standard of care," said Eric Schadt, Ph.D., founder and chief executive officer of Sema4 in a statement.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Sema4

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Sema4 in 3 CB Insights research briefs, most recently on Dec 14, 2020.

Expert Collections containing Sema4

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sema4 is included in 6 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

U

Unicorns- Billion Dollar Startups

771 items

M

Medical Devices

8,341 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health & Wellness Assessment Tools

2,094 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes providers.

D

Digital Health 150 (2020)

150 items

The winners of the second annual CB Insights Digital Health 150.

O

Omics

975 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Sema4 Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sema4 Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.